Literature DB >> 12213987

Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction.

A H Wu1, D L Morris, D R Fletcher, F S Apple, R H Christenson, P C Painter.   

Abstract

Human albumin has the ability to bind cobalt at the N-terminus. The exposure of circulating albumin to ischemic tissue alters the ability of albumin to bind cobalt, probably through a mechanism involving free-radical production. The Albumin Cobalt Binding (ACB) test measures the alteration in albumin metal binding, and elevation of the ACB test is thought to be an early indicator of myocardial ischemia. In a previous multicenter study of chest pain patients presenting to the emergency department (ED), this test demonstrated high negative predictive value and sensitivity in the sample collected at presentation for predicting cardiac troponin I (cTnI)-negative or cTnI-positive results 6-24 h later. Since the completion of that report, the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) have redefined the criteria for the diagnosis of acute myocardial infarction (AMI). The data from the multicenter ACB study were re-examined using the new diagnostic criteria for AMI to determine if combining the ACB test with troponin improved the sensitivity of either assay used alone for early diagnosis of AMI. Assay values were compared to either the final discharge diagnosis made at each site or to a diagnosis of AMI using the strict application of the ESC/ACC guidelines. Using the criterion of physician's discharge diagnosis and using blood collected at ED presentation, the cTnI test alone had a sensitivity of 23.9%, and the ACB test alone had a sensitivity of 39.1%, but the sensitivity significantly increased to 55.9% (p < 0.001 over cTnI alone) when both tests were used in combination. The sensitivity of the combination of ACB and cTnI tests at the 1- to 6-h time-point was 86.7% and at the >6- to 12-h time-point was 93.5%, but they were not significantly improved over the cTnI test alone. In conclusion, using the new ESC/ACC criteria, the combination also resulted in a statistically significant higher diagnostic sensitivity on blood collected at presentation. These data indicate a possible role of the ACB test in the early triage of patients with chest pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12213987     DOI: 10.1385/ct:1:2:147

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  7 in total

1.  Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome.

Authors:  Andrew Worster; P J Devereaux; Diane Heels-Ansdell; Gordon H Guyatt; John Opie; Farouk Mookadam; Stephen A Hill
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

2.  Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma.

Authors:  M Can; S Demirtas; O Polat; A Yildiz
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

3.  The protective effect of tadalafil on IMA (ischemia modified albumin) levels in experimental renal ischemia-reperfusion injury.

Authors:  Akin Soner Amasyali; Abdullah Akkurt; Ercan Kazan; Mustafa Yilmaz; Bulent Erol; Yuksel Yildiz; Haluk Erol
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  The PRIMA study: presentation ischaemia-modified albumin in the emergency department.

Authors:  L Keating; J R Benger; R Beetham; S Bateman; S Veysey; J Kendall; R Pullinger
Journal:  Emerg Med J       Date:  2006-10       Impact factor: 2.740

5.  Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes.

Authors:  Cui Liyan; Zhang Jie; Wu Yonghua; Hu Xiaozhou
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

6.  Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes.

Authors:  M K Sinha; D Roy; D C Gaze; P O Collinson; J C Kaski
Journal:  Emerg Med J       Date:  2004-01       Impact factor: 2.740

7.  Ischemia modified albumin: does it change during pneumoperitoneum in robotic prostatectomies?

Authors:  Serpil Ustalar Ozgen; Bora Ozveren; Meltem Kilercik; Ugur Aksu; Binnaz Ay; Ilter Tufek; Ali Riza Kural; Levent N Turkeri; Fevzi Toraman
Journal:  Int Braz J Urol       Date:  2016 Jan-Feb       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.